Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2019

01-07-2019 | Craniotomy | Clinical trial

Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases

Authors: Maria J. Sambade, Grace Prince, Allison M. Deal, Dimitri Trembath, Megan McKee, Amy Garrett, Kevin Keith, Juanita Ramirez, Bentley Midkiff, Kimberly Blackwell, Sarah Sammons, Jose Pablo Leone, Adam Brufsky, Aki Morikawa, Edi Brogi, Andrew Seidman, Matthew Ewend, Lisa A. Carey, Stergios J. Moschos, Ronald L. Hamilton, Benjamin Vincent, Carey Anders

Published in: Breast Cancer Research and Treatment | Issue 2/2019

Login to get access

Abstract

Purpose

Brain metastases (BM) are a complication of advanced breast cancer (BC). Histology of melanoma BM offers prognostic value; however, understanding the microenvironment of breast cancer brain metastases (BCBM) is less characterized. This study reports on four histological biomarkers, gliosis, immune infiltrate, hemorrhage, necrosis, and their prognostic significance in BCBM.

Methods

A biobank of 203 human tissues from patients who underwent craniotomy for BCBM was created across four academic institutions. Degree of gliosis, immune infiltrate, hemorrhage, and necrosis were identified and scored via representative H&E stain (0–3+). Overall survival (OS) was estimated using the Kaplan–Meier method. Cox proportional hazards regression evaluated prognostic value of the biomarkers in the context of standard clinical characteristics.

Results

BCBM subtype (available for n = 158) was 36% Her2+, 26% hormone receptor (HR)+/Her2− 38% HR−/Her2− (triple negative, TN). Gliosis was observed in 82% (116/141) of BCBM, with immune infiltrate 44% (90/201), hemorrhage 82% (166/141), and necrosis 87% (176/201). Necrosis was significantly higher in TNBC (p < 0.01). Presence of gliosis, immune infiltrate, and hemorrhage correlated with improved OS (p = 0.03, p = 0.03, p = 0.1), while necrosis correlated with inferior OS (p = 0.01). Improved OS was associated with gliosis in TN (p = 0.02), and immune infiltrate (p = 0.001) and hemorrhage (p = 0.07) in HER2+. In a multivariable model for OS, incorporating these biomarkers with traditional clinical variables improved the model fit (p < 0.001).

Conclusion

Gliosis confers superior prognosis in TNBC BM; immune infiltrate and hemorrhage correlate with superior prognosis in HER2+ BCBM. Understanding the metastatic microenvironment of BCBM refines prognostic considerations and may unveil novel therapeutic strategies.
Literature
1.
go back to reference Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Goncalves A (2012) Recent trends in epidemiology of brain metastases: an overview. Anticancer Res 32(11):4655–4662PubMed Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Goncalves A (2012) Recent trends in epidemiology of brain metastases: an overview. Anticancer Res 32(11):4655–4662PubMed
2.
go back to reference Sperduto PW, Kased N, Roberge D, Chao ST, Shanley R, Luo X et al (2013) The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neurooncol 112(3):467–472CrossRefPubMed Sperduto PW, Kased N, Roberge D, Chao ST, Shanley R, Luo X et al (2013) The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neurooncol 112(3):467–472CrossRefPubMed
3.
go back to reference Hamilton R, Krauze M, Romkes M, Omolo B, Konstantinopoulos P, Reinhart T et al (2013) Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 119(15):2737–2746CrossRefPubMedPubMedCentral Hamilton R, Krauze M, Romkes M, Omolo B, Konstantinopoulos P, Reinhart T et al (2013) Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 119(15):2737–2746CrossRefPubMedPubMedCentral
4.
go back to reference Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J et al (2013) Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer 13(4):254–263CrossRefPubMedPubMedCentral Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J et al (2013) Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer 13(4):254–263CrossRefPubMedPubMedCentral
5.
go back to reference Duchnowska R, Peksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B et al (2016) Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res 18(1):43CrossRefPubMedPubMedCentral Duchnowska R, Peksa R, Radecka B, Mandat T, Trojanowski T, Jarosz B et al (2016) Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res 18(1):43CrossRefPubMedPubMedCentral
6.
go back to reference Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976–983CrossRefPubMedPubMedCentral Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M et al (2016) Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17(7):976–983CrossRefPubMedPubMedCentral
7.
go back to reference Neman J, Termini J, Wilczynski S, Vaidehi N, Choy C, Kowolik CM et al (2014) Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc Natl Acad Sci USA 111(3):984–989CrossRefPubMed Neman J, Termini J, Wilczynski S, Vaidehi N, Choy C, Kowolik CM et al (2014) Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc Natl Acad Sci USA 111(3):984–989CrossRefPubMed
8.
go back to reference Gril B, Paranjape AN, Woditschka S, Hua E, Dolan EL, Hanson J et al (2018) Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases. Nat Commun 9(1):2705CrossRefPubMedPubMedCentral Gril B, Paranjape AN, Woditschka S, Hua E, Dolan EL, Hanson J et al (2018) Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases. Nat Commun 9(1):2705CrossRefPubMedPubMedCentral
9.
go back to reference Lyle LT, Lockman PR, Adkins CE, Mohammad AS, Sechrest E, Hua E et al (2016) Alterations in pericyte subpopulations are associated with elevated blood-tumor barrier permeability in experimental brain metastasis of breast cancer. Clin Cancer Res 22(21):5287–5299CrossRefPubMedPubMedCentral Lyle LT, Lockman PR, Adkins CE, Mohammad AS, Sechrest E, Hua E et al (2016) Alterations in pericyte subpopulations are associated with elevated blood-tumor barrier permeability in experimental brain metastasis of breast cancer. Clin Cancer Res 22(21):5287–5299CrossRefPubMedPubMedCentral
Metadata
Title
Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases
Authors
Maria J. Sambade
Grace Prince
Allison M. Deal
Dimitri Trembath
Megan McKee
Amy Garrett
Kevin Keith
Juanita Ramirez
Bentley Midkiff
Kimberly Blackwell
Sarah Sammons
Jose Pablo Leone
Adam Brufsky
Aki Morikawa
Edi Brogi
Andrew Seidman
Matthew Ewend
Lisa A. Carey
Stergios J. Moschos
Ronald L. Hamilton
Benjamin Vincent
Carey Anders
Publication date
01-07-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05211-1

Other articles of this Issue 2/2019

Breast Cancer Research and Treatment 2/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine